Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Vet Med Sci ; 10(4): e1495, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38889089

RESUMEN

BACKGROUND: Dogs with retroperitoneal hemangiosarcoma (HSA) exhibit variable postoperative median survival times (MST). OBJECTIVE: To retrospectively evaluate the prognostic value of selected tumour-related factors, such as tumour size, rupture, invasion into adjacent tissue, involvement of lymph node and distant metastasis, they were analysed in dogs with retroperitoneal HSA. METHODS: Ten dogs with retroperitoneal HSA managed solely with surgical excision were reviewed and compared with spleen (71) and liver (9) HSA. The Kaplan-Meier method and log-rank analysis were used compare MSTs between factors. Multivariable Cox proportional-hazard analysis was used to compare differences between arising sites. RESULTS: Retroperitoneal HSA showed comparatively longer postoperative MST compared with that of spleen and liver HSA and demonstrated significantly longer MST (p = 0.003) for tumours ≥5 cm (195 days) than <5 cm (70 days). Spleen HSA revealed significantly shorter MSTs in involvement of distant lymph nodes (23 days) and distant metastasis (39 days) than those in negative (83 days, p = 0.002 and 110 days, p < 0.001, respectively). Liver HSA also revealed significantly shorter MST (16.5 days compared with 98 days, p = 0.003) for distant metastasis. Additionally, hazard ratios (HRs) and their forest plot for overall HSA revealed as poor prognostic factors, arising sites (spleen; HR 2.78, p = 0.016 and liver; HR 3.62, p = 0.019), involvement of distant lymph nodes (HR 2.43, p = 0.014), and distant metastasis (HR 2.86, p < 0.001), and as better prognostic factor of tumour size ≥5 cm (HR 0.53, p = 0.037). CONCLUSION: In combination with overall HSA, retroperitoneal HSA shows comparatively longer postoperative MST compared to spleen and liver HSA, associated with tumour size ≥5 cm suggesting better prognostic factor.


Asunto(s)
Enfermedades de los Perros , Hemangiosarcoma , Neoplasias Retroperitoneales , Animales , Perros , Hemangiosarcoma/veterinaria , Hemangiosarcoma/patología , Hemangiosarcoma/cirugía , Hemangiosarcoma/mortalidad , Estudios Retrospectivos , Enfermedades de los Perros/patología , Enfermedades de los Perros/cirugía , Enfermedades de los Perros/mortalidad , Masculino , Femenino , Neoplasias Retroperitoneales/veterinaria , Neoplasias Retroperitoneales/patología , Neoplasias Retroperitoneales/cirugía , Neoplasias Retroperitoneales/mortalidad , Pronóstico , Neoplasias del Bazo/veterinaria , Neoplasias del Bazo/cirugía , Neoplasias del Bazo/patología , Neoplasias del Bazo/mortalidad , Neoplasias Hepáticas/veterinaria , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/cirugía , Neoplasias Hepáticas/patología
2.
Br J Haematol ; 204(6): 2222-2226, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38420697

RESUMEN

To address the lack of contemporary population-based epidemiological studies of hepatosplenic T-cell lymphoma (HSTCL), we undertook a population-based study of ICD-O-3-coded HSTCL in England. We used the National Cancer Registration Dataset and linked datasets on hospital admissions, Systemic Anti-Cancer Therapy, socio-demographics, comorbidities and death, identifying cases from 1 January 2013 to 31 December 2019 with survival data up to 5 January 2021. Crude and directly age-standardised incidence rates per million persons per year were calculated. Crude and adjusted incidence rate ratios compared incidence between groups using Poisson regression. A Cox proportional hazards model estimated mortality risks adjusted for age, sex, ethnicity, deprivation and allogenic stem cell transplant (allo-SCT; time varying). We identified 44 patients, mean age 42 years. Median survival was 11 months, and 1 and 5 year survivals were 48% (95% CI 29%-43%) and 22% (95% CI 12%-42%) respectively. The age-standardised incidence was 0.1 per million/year. Incidence was higher in areas with greater deprivation (0.15 per million/year), and more cases than expected were in non-White patients (39%). Non-Whites had a twofold increased risk of death (adjusted hazard ratio 2.21 [95% CI 1.03-4.78]) even after adjusting for deprivation, younger age and allo-SCT. In conclusion, ethnicity and socio-economic status affect both the incidence and survival of HSTCL.


Asunto(s)
Linfoma de Células T , Neoplasias del Bazo , Humanos , Masculino , Femenino , Incidencia , Adulto , Persona de Mediana Edad , Linfoma de Células T/mortalidad , Linfoma de Células T/epidemiología , Linfoma de Células T/terapia , Neoplasias del Bazo/mortalidad , Neoplasias del Bazo/epidemiología , Anciano , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/terapia , Clase Social , Etnicidad/estadística & datos numéricos , Inglaterra/epidemiología , Adulto Joven , Adolescente
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...